DE60118604T2 - Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen - Google Patents
Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen Download PDFInfo
- Publication number
- DE60118604T2 DE60118604T2 DE60118604T DE60118604T DE60118604T2 DE 60118604 T2 DE60118604 T2 DE 60118604T2 DE 60118604 T DE60118604 T DE 60118604T DE 60118604 T DE60118604 T DE 60118604T DE 60118604 T2 DE60118604 T2 DE 60118604T2
- Authority
- DE
- Germany
- Prior art keywords
- blood
- photosensitizer
- dimethyl
- concentration
- fluid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000003860 storage Methods 0.000 title claims description 35
- 230000000415 inactivating effect Effects 0.000 title description 4
- 239000012535 impurity Substances 0.000 title description 2
- 239000003504 photosensitizing agent Substances 0.000 claims abstract description 151
- 239000000654 additive Substances 0.000 claims abstract description 64
- 230000000996 additive effect Effects 0.000 claims abstract description 60
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 34
- 239000008103 glucose Substances 0.000 claims abstract description 33
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims abstract description 32
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract description 19
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims abstract description 6
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 81
- 239000002151 riboflavin Substances 0.000 claims description 80
- 235000019192 riboflavin Nutrition 0.000 claims description 78
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 77
- 210000004369 blood Anatomy 0.000 claims description 76
- 239000008280 blood Substances 0.000 claims description 76
- 239000012530 fluid Substances 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 39
- 239000012503 blood component Substances 0.000 claims description 38
- 238000005202 decontamination Methods 0.000 claims description 35
- 230000003588 decontaminative effect Effects 0.000 claims description 33
- 238000000034 method Methods 0.000 claims description 27
- 239000003146 anticoagulant agent Substances 0.000 claims description 20
- 229940127219 anticoagulant drug Drugs 0.000 claims description 20
- HAUGRYOERYOXHX-UHFFFAOYSA-N Alloxazine Chemical compound C1=CC=C2N=C(C(=O)NC(=O)N3)C3=NC2=C1 HAUGRYOERYOXHX-UHFFFAOYSA-N 0.000 claims description 12
- 230000001954 sterilising effect Effects 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 235000015097 nutrients Nutrition 0.000 claims description 9
- 238000004659 sterilization and disinfection Methods 0.000 claims description 9
- 230000015572 biosynthetic process Effects 0.000 claims description 4
- 125000001452 riboflavin group Chemical group 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims 1
- 230000001678 irradiating effect Effects 0.000 claims 1
- 239000000243 solution Substances 0.000 description 72
- 210000001772 blood platelet Anatomy 0.000 description 70
- 239000000523 sample Substances 0.000 description 41
- 230000002779 inactivation Effects 0.000 description 40
- 239000002609 medium Substances 0.000 description 30
- 230000005855 radiation Effects 0.000 description 30
- 210000002381 plasma Anatomy 0.000 description 27
- 210000004027 cell Anatomy 0.000 description 23
- 239000003634 thrombocyte concentrate Substances 0.000 description 23
- 239000010836 blood and blood product Substances 0.000 description 21
- 244000005700 microbiome Species 0.000 description 21
- 229940125691 blood product Drugs 0.000 description 20
- 210000003743 erythrocyte Anatomy 0.000 description 17
- 229940090993 isolyte s Drugs 0.000 description 16
- GRPSNTXTTSBKGW-BVGHQBMWSA-J magnesium;potassium;sodium;(3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol;triacetate;chloride Chemical compound [Na+].[Mg+2].[Cl-].[K+].CC([O-])=O.CC([O-])=O.CC([O-])=O.OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O GRPSNTXTTSBKGW-BVGHQBMWSA-J 0.000 description 16
- 241000700605 Viruses Species 0.000 description 15
- 239000000306 component Substances 0.000 description 15
- 230000000694 effects Effects 0.000 description 15
- 229910019142 PO4 Inorganic materials 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000004615 ingredient Substances 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 239000010452 phosphate Substances 0.000 description 13
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 13
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 12
- 238000012545 processing Methods 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 10
- 230000006378 damage Effects 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 description 10
- 239000001488 sodium phosphate Substances 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 9
- 230000008033 biological extinction Effects 0.000 description 9
- ZJTJUVIJVLLGSP-UHFFFAOYSA-N lumichrome Chemical compound N1C(=O)NC(=O)C2=C1N=C1C=C(C)C(C)=CC1=N2 ZJTJUVIJVLLGSP-UHFFFAOYSA-N 0.000 description 9
- 239000002504 physiological saline solution Substances 0.000 description 9
- 229910000162 sodium phosphate Inorganic materials 0.000 description 9
- 235000011008 sodium phosphates Nutrition 0.000 description 9
- 238000001228 spectrum Methods 0.000 description 9
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 9
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 8
- 230000004071 biological effect Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 108020004707 nucleic acids Proteins 0.000 description 8
- 102000039446 nucleic acids Human genes 0.000 description 8
- 150000007523 nucleic acids Chemical class 0.000 description 8
- 239000006187 pill Substances 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 241000191963 Staphylococcus epidermidis Species 0.000 description 7
- 238000002617 apheresis Methods 0.000 description 7
- 238000000338 in vitro Methods 0.000 description 7
- 239000001632 sodium acetate Substances 0.000 description 7
- 235000017281 sodium acetate Nutrition 0.000 description 7
- 239000001509 sodium citrate Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 239000002775 capsule Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000000356 contaminant Substances 0.000 description 6
- KPDQZGKJTJRBGU-UHFFFAOYSA-N lumiflavin Chemical compound CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O KPDQZGKJTJRBGU-UHFFFAOYSA-N 0.000 description 6
- 239000001103 potassium chloride Substances 0.000 description 6
- 235000011164 potassium chloride Nutrition 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 6
- 229940038773 trisodium citrate Drugs 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 229940072107 ascorbate Drugs 0.000 description 5
- 239000011668 ascorbic acid Substances 0.000 description 5
- 235000010323 ascorbic acid Nutrition 0.000 description 5
- FVTCRASFADXXNN-SCRDCRAPSA-N flavin mononucleotide Chemical compound OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-SCRDCRAPSA-N 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 150000004032 porphyrins Chemical class 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 239000011550 stock solution Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 241000251169 Alopias vulpinus Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 102000053602 DNA Human genes 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 241000700618 Vaccinia virus Species 0.000 description 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 238000005520 cutting process Methods 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 229910001629 magnesium chloride Inorganic materials 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 239000001301 oxygen Substances 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229960002477 riboflavin Drugs 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 102000008212 P-Selectin Human genes 0.000 description 3
- 108010035766 P-Selectin Proteins 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000004907 flux Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 238000006303 photolysis reaction Methods 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 235000004252 protein component Nutrition 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000010902 straw Substances 0.000 description 3
- 231100000331 toxic Toxicity 0.000 description 3
- 230000002588 toxic effect Effects 0.000 description 3
- RBTBFTRPCNLSDE-UHFFFAOYSA-N 3,7-bis(dimethylamino)phenothiazin-5-ium Chemical compound C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 RBTBFTRPCNLSDE-UHFFFAOYSA-N 0.000 description 2
- MVWNYMTYKBWPHR-UHFFFAOYSA-N 4-methoxy-2,8-dimethyl-1-benzoxonine-6,10,11-triol Chemical compound C1=C(O)C=C(OC)C=C(C)OC2=C(O)C(O)=CC(C)=C21 MVWNYMTYKBWPHR-UHFFFAOYSA-N 0.000 description 2
- 102000004506 Blood Proteins Human genes 0.000 description 2
- 108010017384 Blood Proteins Proteins 0.000 description 2
- 102100037904 CD9 antigen Human genes 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- QEUYATCJHJUQML-UHFFFAOYSA-N acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride;hydrochloride Chemical compound Cl.[Cl-].C1=CC(N)=CC2=NC3=CC(N)=CC=C3C=C21.C1=C(N)C=C2[N+](C)=C(C=C(N)C=C3)C3=CC2=C1 QEUYATCJHJUQML-UHFFFAOYSA-N 0.000 description 2
- 229940002707 acriflavine hydrochloride Drugs 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 108010081181 calcium-binding protein (brain) Proteins 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 150000004775 coumarins Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005281 excited state Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- VWWQXMAJTJZDQX-UYBVJOGSSA-N flavin adenine dinucleotide Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@H](O)[C@@H]1O)O[C@@H]1CO[P@](O)(=O)O[P@@](O)(=O)OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C2=NC(=O)NC(=O)C2=NC2=C1C=C(C)C(C)=C2 VWWQXMAJTJZDQX-UYBVJOGSSA-N 0.000 description 2
- 235000019162 flavin adenine dinucleotide Nutrition 0.000 description 2
- 239000011714 flavin adenine dinucleotide Substances 0.000 description 2
- 229940013640 flavin mononucleotide Drugs 0.000 description 2
- 239000011768 flavin mononucleotide Substances 0.000 description 2
- FVTCRASFADXXNN-UHFFFAOYSA-N flavin mononucleotide Natural products OP(=O)(O)OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O FVTCRASFADXXNN-UHFFFAOYSA-N 0.000 description 2
- 239000004459 forage Substances 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 229960000907 methylthioninium chloride Drugs 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- PGSADBUBUOPOJS-UHFFFAOYSA-N neutral red Chemical compound Cl.C1=C(C)C(N)=CC2=NC3=CC(N(C)C)=CC=C3N=C21 PGSADBUBUOPOJS-UHFFFAOYSA-N 0.000 description 2
- 239000013307 optical fiber Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 150000002990 phenothiazines Chemical class 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 150000004033 porphyrin derivatives Chemical class 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003194 psoralenes Chemical class 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019231 riboflavin-5'-phosphate Nutrition 0.000 description 2
- 229920002477 rna polymer Polymers 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000008279 sol Substances 0.000 description 2
- 239000004575 stone Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 229940066767 systemic antihistamines phenothiazine derivative Drugs 0.000 description 2
- 150000004992 toluidines Chemical class 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241001515965 unidentified phage Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- KUTXFBIHPWIDJQ-BTPXSFBUSA-N (1ar,7as)-7a-methyl-1a-[(e,7r,11r)-3,7,11,15-tetramethylhexadec-2-enyl]naphtho[2,3-b]oxirene-2,7-dione Chemical compound O=C1C2=CC=CC=C2C(=O)[C@@]2(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@]1(C)O2 KUTXFBIHPWIDJQ-BTPXSFBUSA-N 0.000 description 1
- RYAUSSKQMZRMAI-YESZJQIVSA-N (S)-fenpropimorph Chemical compound C([C@@H](C)CC=1C=CC(=CC=1)C(C)(C)C)N1C[C@H](C)O[C@H](C)C1 RYAUSSKQMZRMAI-YESZJQIVSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 description 1
- KFKRXESVMDBTNQ-UHFFFAOYSA-N 3-[18-(2-carboxylatoethyl)-8,13-bis(1-hydroxyethyl)-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-21,24-diium-2-yl]propanoate Chemical class N1C2=C(C)C(C(C)O)=C1C=C(N1)C(C)=C(C(O)C)C1=CC(C(C)=C1CCC(O)=O)=NC1=CC(C(CCC(O)=O)=C1C)=NC1=C2 KFKRXESVMDBTNQ-UHFFFAOYSA-N 0.000 description 1
- UGQFCTZXVAPVCS-UHFFFAOYSA-N 4-amino-2-methyl-1-naphthol Chemical compound C1=CC=CC2=C(O)C(C)=CC(N)=C21 UGQFCTZXVAPVCS-UHFFFAOYSA-N 0.000 description 1
- BUNGCZLFHHXKBX-UHFFFAOYSA-N 8-methoxypsoralen Natural products C1=CC(=O)OC2=C1C=C1CCOC1=C2OC BUNGCZLFHHXKBX-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 241001136792 Alle Species 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 101000623895 Bos taurus Mucin-15 Proteins 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- KSFOVUSSGSKXFI-GAQDCDSVSA-N CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O Chemical compound CC1=C/2NC(\C=C3/N=C(/C=C4\N\C(=C/C5=N/C(=C\2)/C(C=C)=C5C)C(C=C)=C4C)C(C)=C3CCC(O)=O)=C1CCC(O)=O KSFOVUSSGSKXFI-GAQDCDSVSA-N 0.000 description 1
- 101100232929 Caenorhabditis elegans pat-4 gene Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- YJRCNAAPGQBVFS-UHFFFAOYSA-N Cc1cc(O)c(cccc2)c2c1N Chemical compound Cc1cc(O)c(cccc2)c2c1N YJRCNAAPGQBVFS-UHFFFAOYSA-N 0.000 description 1
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 1
- 230000001482 DNA photocleavage Effects 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 240000003517 Elaeocarpus dentatus Species 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- QXKHYNVANLEOEG-UHFFFAOYSA-N Methoxsalen Chemical compound C1=CC(=O)OC2=C1C=C1C=COC1=C2OC QXKHYNVANLEOEG-UHFFFAOYSA-N 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 229940123973 Oxygen scavenger Drugs 0.000 description 1
- 102000013566 Plasminogen Human genes 0.000 description 1
- 108010051456 Plasminogen Proteins 0.000 description 1
- 102100027378 Prothrombin Human genes 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000000999 acridine dye Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000001311 chemical methods and process Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 1
- 229960001076 chlorpromazine Drugs 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002289 effect on microbe Effects 0.000 description 1
- 230000000531 effect on virus Effects 0.000 description 1
- 230000005274 electronic transitions Effects 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- ZINJLDJMHCUBIP-UHFFFAOYSA-N ethametsulfuron-methyl Chemical compound CCOC1=NC(NC)=NC(NC(=O)NS(=O)(=O)C=2C(=CC=CC=2)C(=O)OC)=N1 ZINJLDJMHCUBIP-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940093632 flavin-adenine dinucleotide Drugs 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- FVVLHONNBARESJ-NTOWJWGLSA-H magnesium;potassium;trisodium;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate;acetate;tetrachloride;nonahydrate Chemical compound O.O.O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Mg+2].[Cl-].[Cl-].[Cl-].[Cl-].[K+].CC([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O FVVLHONNBARESJ-NTOWJWGLSA-H 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- DZVCFNFOPIZQKX-LTHRDKTGSA-M merocyanine Chemical compound [Na+].O=C1N(CCCC)C(=O)N(CCCC)C(=O)C1=C\C=C\C=C/1N(CCCS([O-])(=O)=O)C2=CC=CC=C2O\1 DZVCFNFOPIZQKX-LTHRDKTGSA-M 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229960004469 methoxsalen Drugs 0.000 description 1
- SQBBOVROCFXYBN-UHFFFAOYSA-N methoxypsoralen Natural products C1=C2OC(=O)C(OC)=CC2=CC2=C1OC=C2 SQBBOVROCFXYBN-UHFFFAOYSA-N 0.000 description 1
- 239000002991 molded plastic Substances 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 150000004780 naphthols Chemical class 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000002572 peristaltic effect Effects 0.000 description 1
- 239000003016 pheromone Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000000906 photoactive agent Substances 0.000 description 1
- 108010058237 plasma protein fraction Proteins 0.000 description 1
- 229940081857 plasma protein fraction Drugs 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940039716 prothrombin Drugs 0.000 description 1
- 229950003776 protoporphyrin Drugs 0.000 description 1
- -1 psoralenes Chemical class 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000006950 reactive oxygen species formation Effects 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 150000003287 riboflavins Chemical class 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000000176 sodium gluconate Substances 0.000 description 1
- 235000012207 sodium gluconate Nutrition 0.000 description 1
- 229940005574 sodium gluconate Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000009987 spinning Methods 0.000 description 1
- 238000012414 sterilization procedure Methods 0.000 description 1
- 239000012536 storage buffer Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003718 vitamin K5 derivatives Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
- A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
- A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N1/00—Preservation of bodies of humans or animals, or parts thereof
- A01N1/10—Preservation of living parts
- A01N1/12—Chemical aspects of preservation
- A01N1/122—Preservation or perfusion media
- A01N1/124—Disinfecting agents, e.g. antimicrobials
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Dentistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Apparatus For Disinfection Or Sterilisation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/725,426 US6548241B1 (en) | 2000-11-28 | 2000-11-28 | Storage solution containing photosensitizer for inactivation of biological contaminants |
| US725426 | 2000-11-28 | ||
| PCT/US2001/043591 WO2002043485A1 (en) | 2000-11-28 | 2001-11-21 | Storage solution containing photosensitizer for inactivation of biological contaminants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60118604D1 DE60118604D1 (de) | 2006-05-18 |
| DE60118604T2 true DE60118604T2 (de) | 2006-12-14 |
Family
ID=24914504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60118604T Expired - Lifetime DE60118604T2 (de) | 2000-11-28 | 2001-11-21 | Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US6548241B1 (enExample) |
| EP (1) | EP1345491B1 (enExample) |
| JP (1) | JP4473508B2 (enExample) |
| AT (1) | ATE322162T1 (enExample) |
| AU (1) | AU2002225687A1 (enExample) |
| CA (1) | CA2397862C (enExample) |
| DE (1) | DE60118604T2 (enExample) |
| WO (1) | WO2002043485A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030215784A1 (en) * | 1998-07-21 | 2003-11-20 | Dumont Larry Joe | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US20070099170A1 (en) * | 1998-07-21 | 2007-05-03 | Navigant Biotechnologies, Inc. | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
| US7220747B2 (en) * | 1999-07-20 | 2007-05-22 | Gambro, Inc. | Method for preventing damage to or rejuvenating a cellular blood component using mitochondrial enhancer |
| US7094378B1 (en) * | 2000-06-15 | 2006-08-22 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US6969367B2 (en) * | 2000-02-02 | 2005-11-29 | Xepmed, Inc. | Extracorporeal pathogen reduction system |
| US7470245B2 (en) * | 2000-02-02 | 2008-12-30 | Xepmed, Inc. | Extracorporeal pathogen reduction system |
| US6936413B1 (en) * | 2001-12-05 | 2005-08-30 | Baxter International Inc. | Methods and systems for preparing blood products |
| US7183045B2 (en) * | 2002-04-24 | 2007-02-27 | Gambro Inc. | Removal of adenine during a pathogen reduction process in whole blood or red blood cell by dilution |
| CA2524712A1 (en) * | 2003-06-20 | 2004-12-29 | Pall Corporation | Processing of platelet-containing biological fluids |
| US20070102858A1 (en) * | 2005-11-07 | 2007-05-10 | Navigant Biotechnologies, Inc. | Clamps and methods for displacing fluid from portions of fluid containers |
| CA2629340A1 (en) * | 2005-12-06 | 2007-06-14 | Navigant Biotechnologies, Llc | Method for treatment and storage of blood and blood products using endogenous alloxazines and acetate |
| EP1976852A1 (en) | 2006-01-27 | 2008-10-08 | CaridianBCT Biotechnologies, LLC | Methods and compositions for the production of high concentration alloxazine solutions |
| AU2012233032B2 (en) * | 2006-01-27 | 2015-07-16 | Terumo Bct Biotechnologies, Llc | Methods and compositions for the production of high concentration alloxazine solutions |
| US20080234622A1 (en) * | 2007-03-20 | 2008-09-25 | Gambro Bct Inc. | Methods and Systems for Preparing Blood Products |
| US8835104B2 (en) * | 2007-12-20 | 2014-09-16 | Fenwal, Inc. | Medium and methods for the storage of platelets |
| US8968992B2 (en) * | 2008-03-21 | 2015-03-03 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
| US8871434B2 (en) * | 2008-03-21 | 2014-10-28 | Fenwal, Inc. | Red blood cell storage medium for extended storage |
| US20100190676A1 (en) * | 2008-07-22 | 2010-07-29 | Ecolab Inc. | Composition for enhanced removal of blood soils |
| WO2010039994A2 (en) * | 2008-10-01 | 2010-04-08 | Caridianbct, Inc. | Platelet additive solution for leukoreducing white blood cells in apheresed platelets |
| WO2010048572A1 (en) | 2008-10-23 | 2010-04-29 | Cornell University | A novel anti-viral method |
| US8715920B2 (en) | 2010-07-27 | 2014-05-06 | Biovec Transfusion, Llc | Composition for preserving platelets during photosensitization |
| US12089589B2 (en) | 2009-10-12 | 2024-09-17 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US9199016B2 (en) | 2009-10-12 | 2015-12-01 | New Health Sciences, Inc. | System for extended storage of red blood cells and methods of use |
| US11284616B2 (en) | 2010-05-05 | 2022-03-29 | Hemanext Inc. | Irradiation of red blood cells and anaerobic storage |
| US11864553B2 (en) | 2009-10-23 | 2024-01-09 | Fenwal, Inc. | Methods and systems for providing red blood cell products with reduced plasma |
| AU2012240016B2 (en) | 2011-04-07 | 2016-11-10 | Fenwal, Inc. | Automated methods and systems for providing platelet concentrates with reduced residual plasma volumes and storage media for such platelet concentrates |
| EP4190154A1 (en) * | 2011-07-05 | 2023-06-07 | Hemanext Inc. | A system for extended storage of red blood cells |
| US8940228B2 (en) | 2012-01-11 | 2015-01-27 | Terumo Bct, Inc. | Slidable clamp for port isolation |
| US9289546B2 (en) * | 2012-08-16 | 2016-03-22 | Dirk Jerome Erickson | Exsanguination preventing device |
| WO2015191599A2 (en) | 2014-06-09 | 2015-12-17 | Terumo Bct, Inc. | Lyophilization |
| WO2016145210A1 (en) | 2015-03-10 | 2016-09-15 | New Health Sciences, Inc. | Oxygen reduction disposable kits, devices and methods of use thereof |
| IL285359B2 (en) | 2015-04-23 | 2024-01-01 | Hemanext Inc | Anaerobic blood storage containers |
| US20190099543A1 (en) | 2016-03-23 | 2019-04-04 | Terumo Kabushiki Kaisha | Light irradiation device |
| IL273433B2 (en) * | 2017-09-20 | 2025-01-01 | Cerus Corp | Compositions and methods for inactivating platelet pathogens |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2786014A (en) | 1952-09-10 | 1957-03-19 | James L Tullis | Platelet preservation |
| US3629071A (en) | 1970-02-10 | 1971-12-21 | Upjohn Co | Storage-stable hemostatic transfusion suspensions of blood platelets, glucose, magnesium chloride and certain prostaglandins |
| US3874384A (en) | 1971-11-01 | 1975-04-01 | American Hospital Supply Corp | Improved blood storage unit and method of storing blood |
| DE2532183C3 (de) | 1975-07-18 | 1982-03-04 | Behringwerke Ag, 3550 Marburg | Polyionische isotonische Salzlösung zur Konservierung von Erythrozyten oder zur Perfusion und zur Konservierung von zur Transplantion bestimmter Organen |
| US4112070A (en) | 1977-06-08 | 1978-09-05 | Research Corporation | Blood preservation system |
| GB2034463B (en) | 1978-11-11 | 1983-03-30 | Ryan W | Plaetelet reference control |
| US4267269A (en) | 1980-02-05 | 1981-05-12 | Baxter Travenol Laboratories, Inc. | Red cell storage solution |
| US4568542A (en) | 1981-06-09 | 1986-02-04 | Lee Biomolecular Research Laboratories, Inc. | Vaccine compositions |
| US4390619A (en) | 1981-09-28 | 1983-06-28 | James Clifford Haight | Leukocyte or platelet storage using ion-exchange resins |
| JPS5862333A (ja) * | 1981-10-09 | 1983-04-13 | Mazda Motor Corp | エンジンのアイドル回転制御装置 |
| US4432750A (en) | 1981-12-02 | 1984-02-21 | Baxter Travenol Laboratories, Inc. | Additive sterol solution and method for preserving normal red cell morphology in whole blood during storage |
| DE3225408A1 (de) | 1982-07-07 | 1984-01-12 | Biotest-Serum-Institut Gmbh, 6000 Frankfurt | Waessrige loesung zum suspendieren und lagern von zellen, insbesondere erythrozyten |
| CA1216518A (en) | 1982-11-01 | 1987-01-13 | Gail A. Rock | Plasma-free medium for platelet storage |
| US4748120A (en) | 1983-05-02 | 1988-05-31 | Diamond Scientific Co. | Photochemical decontamination treatment of whole blood or blood components |
| US4609372A (en) | 1983-10-13 | 1986-09-02 | Miles Laboratories, Inc. | Heat sterilizable storage solution for red blood cells |
| GB8328495D0 (en) | 1983-10-25 | 1983-11-23 | Wellcome Found | Pharmacologically active ketones |
| CA1244774A (en) * | 1983-11-09 | 1988-11-15 | Thomas Jefferson University | Medium for storing blood platelets |
| US4828976A (en) | 1983-12-29 | 1989-05-09 | Thomas Jefferson University | Glucose free media for storing blood platelets |
| US4992363A (en) | 1983-11-09 | 1991-02-12 | Thomas Jefferson University | Method for preparing glucose free media for storing blood platelets |
| US4585735A (en) | 1984-07-19 | 1986-04-29 | American National Red Cross | Prolonged storage of red blood cells |
| JPS61275228A (ja) | 1985-03-14 | 1986-12-05 | バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテツド | 治療用タンパク組成物中のビ−ルスの光動的不活性化 |
| US4704352A (en) | 1985-06-25 | 1987-11-03 | Baxter Travenol Laboratories, Inc. | L-ascorbate-2-phosphate salts in blood cell storage |
| US4675185A (en) | 1985-12-06 | 1987-06-23 | Baxter Travenol Laboratories, Inc. | Solution for stabilizing red blood cells during storage |
| US5281392A (en) | 1986-03-10 | 1994-01-25 | Rubinstein Alan I | Method for disinfecting red blood cells, blood products, and corneas |
| US4695460A (en) * | 1986-03-19 | 1987-09-22 | American Red Cross | Synthetic, plasma-free, transfusible platelet storage medium |
| US4961928A (en) | 1986-03-19 | 1990-10-09 | American Red Cross | Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
| US5248506A (en) | 1986-03-19 | 1993-09-28 | American National Red Cross | Synthetic, plasma-free, transfusible storage medium for red blood cells and platelets |
| US4769318A (en) | 1986-06-03 | 1988-09-06 | Ube Industries, Ltd. | Additive solution for blood preservation and activation |
| US4726949A (en) | 1986-08-26 | 1988-02-23 | Baxter Travenol Laboratories, Inc. | Irradiation of blood products |
| DE3805459A1 (de) | 1988-02-22 | 1989-08-31 | Biotest Pharma Gmbh | Verfahren zur sterilisation von blut, plasma, blut- und plasmaderivaten, zellsuspensionen oder dgl. |
| US4994367A (en) | 1988-10-07 | 1991-02-19 | East Carolina University | Extended shelf life platelet preparations and process for preparing the same |
| US5211960A (en) | 1988-11-29 | 1993-05-18 | Scripps Clinic And Research Foundation | Stabilization of leukocytes |
| US5041078A (en) | 1989-03-06 | 1991-08-20 | Baylor Research Foundation, A Nonprofit Corporation Of The State Of Texas | Photodynamic viral deactivation with sapphyrins |
| US4999375A (en) | 1989-04-11 | 1991-03-12 | Hoffmann-La Roche Inc. | Psoralen reagent compositions for extracorporeal treatment of blood |
| US4925665A (en) | 1989-06-22 | 1990-05-15 | Thomas Jefferson University | Glucose free primary anticoagulant for blood containing citrate ions |
| US5250303A (en) | 1989-10-06 | 1993-10-05 | The American National Red Cross | Procedure for storing red cells with prolonged maintenance of cellular concentrations of ATP and 2,3 DPG |
| US5236716A (en) | 1990-02-12 | 1993-08-17 | Miles Inc. | Platelets concentrate with low white blood cells content |
| US5147776A (en) | 1990-02-26 | 1992-09-15 | University Of Iowa Research Foundation | Use of 2,5-anhydromannitol for control of pH during blood storage |
| US5418130A (en) | 1990-04-16 | 1995-05-23 | Cryopharm Corporation | Method of inactivation of viral and bacterial blood contaminants |
| US5516629A (en) | 1990-04-16 | 1996-05-14 | Cryopharm Corporation | Photoinactivation of viral and bacterial blood contaminants using halogenated coumarins |
| US5798238A (en) | 1990-04-16 | 1998-08-25 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants with quinolines as photosensitizer |
| US5587490A (en) | 1990-04-16 | 1996-12-24 | Credit Managers Association Of California | Method of inactivation of viral and bacterial blood contaminants |
| US5342752A (en) | 1990-04-16 | 1994-08-30 | Cryopharm Corporation | Method of inactivation of viral blood contaminants using acridine deriatives |
| US5955256A (en) | 1990-04-16 | 1999-09-21 | Baxter International Inc. | Method of inactivation of viral and bacterial blood contaminants |
| US5545516A (en) * | 1990-05-01 | 1996-08-13 | The American National Red Cross | Inactivation of extracellular enveloped viruses in blood and blood components by phenthiazin-5-ium dyes plus light |
| US6077659A (en) | 1990-05-15 | 2000-06-20 | New York Blood Center, Inc. | Vitamin E and derivatives thereof prevent potassium ion leakage and other types of damage in red cells that are virus sterilized by phthalocyanines and light |
| US5120649A (en) | 1990-05-15 | 1992-06-09 | New York Blood Center, Inc. | Photodynamic inactivation of viruses in blood cell-containing compositions |
| US5658722A (en) | 1990-05-15 | 1997-08-19 | New York Blood Center, Inc. | Process for the sterilization of biological compositions using UVA1 irradiation |
| US5232844A (en) | 1990-05-15 | 1993-08-03 | New York Blood Center | Photodynamic inactivation of viruses in cell-containing compositions |
| DE69126861T2 (de) | 1990-11-07 | 1998-02-26 | Baxter Int | Lösung zur aufbewahrung roter blutzellen |
| CA2071835A1 (en) | 1990-11-07 | 1992-05-08 | Gerald A. Grode | Blood platelet storage medium |
| AU646533B2 (en) | 1990-12-20 | 1994-02-24 | Baxter International Inc. | Systems for eradicating contaminants in fluids |
| US5376524A (en) | 1991-04-01 | 1994-12-27 | Thomas Jefferson University | Platelet storage medium containing acetate and phosphate |
| US5569579A (en) | 1991-04-01 | 1996-10-29 | Thomas Jefferson University | Synthetic-based platelet storage media |
| FR2715303A1 (fr) | 1991-04-02 | 1995-07-28 | Berque Jean | Utilisation du FAD et/ou du NAD comme médicaments. |
| FR2674753B1 (fr) | 1991-04-02 | 1995-03-10 | Jean Berque | Nouvelles indications therapeutiques, en particulier pour le traitement du sida, d'un medicament deja existant et fabrique a partir d'une molecule denuee de contre-indications et d'effets indesirables. |
| WO1992019355A1 (en) | 1991-05-08 | 1992-11-12 | Baxter International Inc. | Methods for processing red blood cell products for long term storage free of microorganisms |
| NZ244270A (en) | 1991-09-13 | 1995-07-26 | Eisai Co Ltd | Injectable composition comprising riboflavin |
| US5474891A (en) | 1991-10-30 | 1995-12-12 | Thomas Jefferson University | Plasma-based platelet concentrate preparations with additive |
| US5344752A (en) | 1991-10-30 | 1994-09-06 | Thomas Jefferson University | Plasma-based platelet concentrate preparations |
| US5234808A (en) | 1991-10-30 | 1993-08-10 | Thomas Jefferson University | Acetate addition to platelets stored in plasma |
| US5247178A (en) | 1991-12-12 | 1993-09-21 | Fusion Systems Corporation | Method and apparatus for treating fluids by focusing reflected light on a thin fluid layer |
| US5459030A (en) | 1992-03-02 | 1995-10-17 | Steritech, Inc. | Synthetic media compositions for inactivating bacteria and viruses in blood preparations with 8-methoxypsoralen |
| WO1996014740A1 (en) | 1992-03-02 | 1996-05-23 | Cerus Corporation | Synthetic media for blood components |
| US5288605A (en) | 1992-03-02 | 1994-02-22 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
| US5618662A (en) | 1992-03-02 | 1997-04-08 | Cerus Corporation | Intravenous administration of psoralen |
| SE9201413L (sv) | 1992-04-30 | 1993-10-31 | Stiftelsen Foer Medicinsk Tekn | Beredning och sätt för aferesframställning av trombocytkoncentrat med väsentligt förlängd hållbarhet |
| US5378601A (en) | 1992-07-24 | 1995-01-03 | Montefiore Medical Center | Method of preserving platelets with apyrase and an antioxidant |
| WO1994003054A1 (en) | 1992-08-07 | 1994-02-17 | Steritech, Inc. | Methods for inactivating bacteria in blood preparations with 8-methoxypsoralen |
| TW262386B (enExample) | 1992-09-30 | 1995-11-11 | Senju Pharma Co | |
| US5358844A (en) | 1993-02-18 | 1994-10-25 | Brigham And Women's Hospital, Inc. | Preservation of blood platelets |
| US5871900A (en) | 1993-06-28 | 1999-02-16 | Cerus Corporation | Method of inactivating pathogens in biological fluids using photoactivated 5-primaryamino psoralens |
| US5593823A (en) | 1993-06-28 | 1997-01-14 | Cerus Corporation | Method for inactivating pathogens in blood using photoactivation of 4'-primary amino-substituted psoralens |
| US5712085A (en) | 1993-06-28 | 1998-01-27 | Cerus Corporation | 5'-(4-amino-2-oxa)butye-4,4', 8-trinethylpsoralen in synthetic medium |
| US6004741A (en) | 1993-06-28 | 1999-12-21 | Cerus Corporation | Method for the photoactivation of 4' and 5' primary aminoalkyl psoralens in platelet preparations |
| DE69534151T2 (de) | 1994-02-22 | 2006-01-12 | Nippon Telegraph And Telephone Corp. | Gefriergetrocknete Blutzellen, Stammzellen und Plättchen und Verfahren zu deren Herstellung |
| FR2718353B3 (fr) | 1994-04-11 | 1996-06-28 | Jean Berque | Compositions pharmaceutiques à base de produits biologiques atoxiques destinées à la protection locale des muqueuses génitales et rectales. |
| US5709992A (en) | 1994-08-17 | 1998-01-20 | Rubinstein; Alan I. | Method for disinfecting red blood cells |
| US5622867A (en) | 1994-10-19 | 1997-04-22 | Lifecell Corporation | Prolonged preservation of blood platelets |
| US5919614A (en) | 1994-10-19 | 1999-07-06 | Lifecell Corporation | Composition comprising three platelet lesion inhibitors for platelet storage |
| EP0793414A2 (en) | 1994-11-14 | 1997-09-10 | Pall Corporation | Long-term blood component storage system and method |
| US5691132A (en) | 1994-11-14 | 1997-11-25 | Cerus Corporation | Method for inactivating pathogens in red cell compositions using quinacrine mustard |
| JP4041171B2 (ja) * | 1994-12-14 | 2008-01-30 | 日本赤十字社 | 血小板保存液 |
| US5605934A (en) | 1995-03-23 | 1997-02-25 | Baxter International Inc. | Method of manufacturing and storing solutions |
| US5624794A (en) | 1995-06-05 | 1997-04-29 | The Regents Of The University Of California | Method for extending the useful shelf-life of refrigerated red blood cells by flushing with inert gas |
| US5656154A (en) | 1995-06-07 | 1997-08-12 | Organ, Inc. | Method and apparatus for separating a fluid into components and for washing a material |
| WO1997000679A1 (en) | 1995-06-23 | 1997-01-09 | Medichem Research, Inc. | Biflavanoids and derivatives thereof as antiviral agents |
| JP2930908B2 (ja) | 1995-07-19 | 1999-08-09 | 川澄化学工業株式会社 | 血小板保存液 |
| US5736313A (en) | 1995-10-20 | 1998-04-07 | The United States Of America As Represented By The Secretary Of The Navy | Method of lyophilizing platelets by incubation with high carbohydrate concentrations and supercooling prior to freezing |
| US5834198A (en) | 1996-03-21 | 1998-11-10 | Boehringer Mamnnheim Gmbh | Selective photoinducted flavin-dependent cleavage of RNA at G-U base pairs and kits therefor |
| US6060233A (en) | 1996-06-14 | 2000-05-09 | Biostore New Zealand, Ltd | Methods for the lyophilization of platelets, platelet membranes or erythrocytes |
| US5783093A (en) | 1997-01-02 | 1998-07-21 | Haemonetics Corporation | Blood cell concentrates using a single solution for anticoagulation and preservation |
| WO1998031219A1 (en) * | 1997-01-21 | 1998-07-23 | The American National Red Cross | Intracellular and extracellular decontamination of whole blood and blood components by amphiphilic phenothiazin-5-ium dyes plus light |
| US6605699B1 (en) * | 1997-01-21 | 2003-08-12 | Human Genome Sciences, Inc. | Galectin-11 polypeptides |
| US5789151A (en) | 1997-05-15 | 1998-08-04 | The Regents Of The University Of California | Prolonged cold storage of red blood cells by oxygen removal and additive usage |
| US6063624A (en) | 1997-06-09 | 2000-05-16 | Baxter International Inc. | Platelet suspensions and methods for resuspending platelets |
| US5922256A (en) * | 1997-06-26 | 1999-07-13 | Textron Automotive Company, Inc. | Molding method for making plastic foam-backed shells |
| US5955257A (en) | 1997-10-21 | 1999-09-21 | Regents Of The University Of Minnesota | Infusible grade short-term cell storage medium for mononuclear cells |
| US7094378B1 (en) * | 2000-06-15 | 2006-08-22 | Gambro, Inc. | Method and apparatus for inactivation of biological contaminants using photosensitizers |
| US6268120B1 (en) * | 1999-10-19 | 2001-07-31 | Gambro, Inc. | Isoalloxazine derivatives to neutralize biological contaminants |
-
2000
- 2000-11-28 US US09/725,426 patent/US6548241B1/en not_active Expired - Lifetime
-
2001
- 2001-11-21 DE DE60118604T patent/DE60118604T2/de not_active Expired - Lifetime
- 2001-11-21 JP JP2002545475A patent/JP4473508B2/ja not_active Expired - Lifetime
- 2001-11-21 AU AU2002225687A patent/AU2002225687A1/en not_active Abandoned
- 2001-11-21 EP EP01995177A patent/EP1345491B1/en not_active Expired - Lifetime
- 2001-11-21 WO PCT/US2001/043591 patent/WO2002043485A1/en not_active Ceased
- 2001-11-21 AT AT01995177T patent/ATE322162T1/de not_active IP Right Cessation
- 2001-11-21 CA CA2397862A patent/CA2397862C/en not_active Expired - Lifetime
-
2003
- 2003-02-25 US US10/374,907 patent/US20040023201A9/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002043485A1 (en) | 2002-06-06 |
| JP4473508B2 (ja) | 2010-06-02 |
| US20040023201A9 (en) | 2004-02-05 |
| JP2004514680A (ja) | 2004-05-20 |
| EP1345491B1 (en) | 2006-04-05 |
| DE60118604D1 (de) | 2006-05-18 |
| AU2002225687A1 (en) | 2002-06-11 |
| US20030186213A1 (en) | 2003-10-02 |
| EP1345491A1 (en) | 2003-09-24 |
| ATE322162T1 (de) | 2006-04-15 |
| US6548241B1 (en) | 2003-04-15 |
| CA2397862C (en) | 2013-04-16 |
| CA2397862A1 (en) | 2002-06-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60118604T2 (de) | Photosensibilisator-enthaltende lagerungslösung zur inaktivierung von biologischen verunreinigungen | |
| DE60124095T2 (de) | Verfahren zur inaktivierung von mikroorganismen unter verwendung von photosensibilisatoren | |
| DE69432832T2 (de) | Vorrichtung und verfahren zur photoaktivierung | |
| DE69328685T2 (de) | Verfahren zur inaktivierung von bakterien in blutpräparaten mit hilfe von methoxypsoralen | |
| DE69328777T2 (de) | Dekontaminierung von Plättchen mit 8-Methoxypsoralen | |
| DE3855220T2 (de) | Methode zur beseitigung von infektionserregern in geweben | |
| DE69533942T2 (de) | Behandlung von lösungen roter blutkörperchen mit antiviralen wirkstoffen | |
| EP2174669B1 (en) | System for treating a fluid for inactivation of biological contaminats using photosensitizers | |
| US4915683A (en) | Antiviral method, agents and apparatus | |
| DE69432351T2 (de) | Verfahren zum sterilisieren von produkten | |
| DE69826521T2 (de) | Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien | |
| EP0544895A1 (en) | PROCESS FOR INACTIVATION OF PATHOGENIC GERM IN A BIOLOGICAL LIQUID. | |
| EP1047458A2 (en) | Method for inactivation of microorganisms using photosensitizers | |
| WO2001094349A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
| US20030215784A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
| US7985588B2 (en) | Induction of and maintenance of nucleic acid damage in pathogens using riboflavin and light | |
| JP2004520448A (ja) | 酸化防止剤を使用するウイルスの不活性化法 | |
| US20030073650A1 (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers | |
| DE60209264T2 (de) | Herstellung von impfstoffen mittels photosensitizer und licht | |
| DE69813634T2 (de) | Entfernung von desinfektionsfarben | |
| US8044051B2 (en) | Methods and compositions for the production of high concentration alloxazine solutions | |
| AU2012233033B2 (en) | Methods and compositions for the production of high concentration alloxazine solutions | |
| AU4583802A (en) | Method and apparatus for inactivation of biological contaminants using photosensitizers |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8327 | Change in the person/name/address of the patent owner |
Owner name: NAVIGANT BIOTECHNOLOGIES, LLC (N.D.GES.D. STAA, US |
|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: CARIDIANBCT BIOTECHNOLOGIES.LLC (N. D. GES.D. , US |
|
| R082 | Change of representative |
Ref document number: 1345491 Country of ref document: EP Representative=s name: SCHWABE SANDMAIR MARX, DE |